Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.85 +0.18%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $100.62 million.
GUIDANCE:
Corcept Therapeutics sees FY2022 revenue of $400-430 million, versus the consensus of $414.4 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Nike names former Pfizer CFO David Denton as new finance chief
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
